Correction
for
Ratzinger et al., J Immunol 173 (4) 2780-2791.
The Journal of Immunology, 2005, 174: 3818.
Copyright © 2005 by The American Association of Immunologists, Inc.
Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells.
Gundrun Ratzinger,
Jan Baggers,
Maria A. de Cos,
Jianda Yuan,
Tao Dao,
John L. Reagan,
Christian Münz,
Glenn Heller and
James W. Young
Gundrun Ratzinger, Jan Baggers, Maria A. de Cos, Jianda Yuan, Tao Dao, John L. Reagan, Christian Münz, Glenn Heller, and James W. Young. Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells. The Journal of Immunology, 2004, 173: 2780–2791
.
In Materials and Methods, in the third sentence of the third paragraph under the heading Cell purification and generation of DCs (Fig. 5), an error was made in the cytokine dosage. The dosage for FLT-3 ligand is nanograms per milliliters instead of micrograms per milliliters. The correct sentence is shown below.
Specific cytokine supplements used in common for generating both LCs and DDC-IDCs included GM-CSF (1000 IU/ml), TNF-
(5 ng/ml), c-kit ligand (20 ng/ml), and FLT-3 ligand (50 nanograms/ml).
